logo
Share SHARE
FONT-SIZE Plus   Neg

AVI BioPharma's Eteplirsen Meets PrimaryEndpoint For Duchenne Muscular Dystrophy

AVI BioPharma Inc. (AVII: Quote), a developer of RNA-based therapeutics, reported that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy or DMD. Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistically significant increase in novel dystrophin compared to no increase in the placebo group.

In the study, a shorter duration of eteplirsen treatment, 12 weeks, did not show a significant increase in novel dystrophin, despite administration of the drug at a higher dose, the company added. This finding suggests that a longer duration of dosing is required before meaningful levels of dystrophin are produced.

Eteplirsen is AVI's lead drug candidate that is systemically delivered for the treatment of a substantial subgroup of patients with DMD.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
If calories are not reduced, exercise alone can have no effect on obesity, says British Sports Medicine, a peer-reviewed journal of sport and exercise medicine. The journal says the blame for expanding waist lines is directly on the type and amount of calories consumed and the poor diet generates more disease than physical inactivity, alcohol and smoking combined. Deutsche Bank (DB) on Sunday reported an about 50 percent decline in first-quarter profit, despite clocking double-digit revenue growth, as the German lender recorded hefty legal charges over allegations of rate-rigging. Casino operator Wynn Resorts said its shareholders ousted Elaine Wynn from the board, reflecting fears that her presence may lead to disharmony with the management.
comments powered by Disqus
Follow RTT